

| Contractor Details  | Type/ size of legal entity | Place of performance of contract activities   | Logo  |
|---|----------------------------|---|---|
| <p><u>Main contractor</u></p> <p>BC Platforms AG<br/>Dreikönigstrasse 31A, CH-8002, Zurich, Switzerland<br/>Henrik Plym-Forshell<br/>+467051072732<br/><a href="mailto:henrik.plym-forshell@bcplatforms.com">henrik.plym-forshell@bcplatforms.com</a></p> | SME                        | <p>% of contract value allocated to BC Platforms as main contractor:<br/>Lot 3: 55%, Lot 4: 15%</p> <p>% of activities for the contract performed by the main contractor in EU Member States or countries associated with Horizon 2020: 100 %</p> |    |
| <p><u>Other consortium member(s)</u></p> <p>Eufomatics Oy<br/>Tekniikantie 12, 02150 Espoo, Finland<br/>Tommi Kaasalainen<br/>+358504861210<br/><a href="mailto:Tommi.kaasalainen@eufomatics.com">Tommi.kaasalainen@eufomatics.com</a></p>                | SME                        | <p>% of contract value allocated to Eufomatics: Lot 3: 30%, Lot 4: 35%</p> <p>% of activities for the contract performed by contractor Eufomatics in EU Member States or countries associated with Horizon 2020: 100%</p>                         |  |
| <p><u>Other consortium member(s)</u></p> <p>Oncompass Medicine Hungary Kft.<br/>Budapest, Retek u. 34, 1024 Hungary<br/>Istvan Petak<br/>+36305411063<br/><a href="mailto:Istvan.petak@oncompassme">Istvan.petak@oncompassme</a></p>                      | SME                        | <p>% of contract value allocated to Oncompass: Lot 3: 15%, Lot 4: 50%</p> <p>% of activities for the contract performed by contractor Oncompass in EU Member States or countries associated with Horizon 2020: 100%</p>                           |  |

[dicine.com](http://dicine.com)

## Project abstract

BC Platforms, Euformatics and Oncompass Medicine have decided to form a consortium as leading European SMEs that together represent the state of the art and beyond for functionality corresponding to Lots 3+4. We will supplement this with new innovations for the project, meeting and exceeding the requirements. BC Platforms (BCP) and Euformatics (EUF) have R&D operations in Finland and Oncompass Medicine (OCM) has R&D operation in Hungary. The Tender identifier "EU ONCO-PLATFORM" is meant to reflect all three companies (EUformatics-ONCOmpass-BC PLATFORMs).

In Lot 3 our consortium possesses tools already meeting many requirements of the NGS4P RfT Lot3 in terms of technical and user needs. The planned innovations will add novel features and modules to a base of already existing tools.

In Lot 4, EU Onco-Platform provides a unique opportunity to realise precision oncology at and beyond state of the art in terms of reporting and e-medication. All members have years of experience in clinical reporting of NGS results, and there is a significant synergy among the members with different backgrounds and business areas. Proven by the pre-existing reporting tools, all members are capable of innovating and meeting patients' and carers' needs in terms of reporting NGS results.

## Previous EU funding

Is the project based on / a continuation of R&D activities that were previously funded by the EU?: NO

